Continuing Care and Treatment for Patients With Cancer/AIDS/Skin Disease
NCT ID: NCT00001295
Last Updated: 2019-12-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
2145 participants
OBSERVATIONAL
1992-01-29
2016-08-23
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
It may be in the interest of the CCR to continue to follow and treat certain subjects after they have completed their treatment and participation on a research protocol.
Objective:
To provide continuing treatment and medical follow-up for CCR subjects who have completed their treatment and participation on a research protocol and who are not currently entered on or eligible for another active research protocol.
Eligibility:
Subjects who have been previously enrolled on and received treatment according to an approved CCR research protocol. (clinical trial)
It is in the best interest of the subject and the CCR for the subject to continue to receive standard care and follow-up at the NIH.
Design:
Medical/surgical/radiotherapeutic care, treatment and follow-up is provided for CCR subjects who have completed their treatment and participation on a research protocol and who are not currently entered on an active research protocol.
No investigational treatments will be administered. This protocol is not be used as a platform to perform pilot studies of off-label uses for standard agents.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
It is in the best interests of the subject and the CCR for the subject to continue to receive treatment and follow-up at the NIH.
The subject or guardian signs the informed consent and agrees to the proposed treatment regimen.
Exclusion Criteria
Subjects who are receiving an investigational therapy.
99 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Caryn Steakley, R.N.
Role: PRINCIPAL_INVESTIGATOR
National Cancer Institute (NCI)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
92-C-0094
Identifier Type: -
Identifier Source: secondary_id
920094
Identifier Type: -
Identifier Source: org_study_id